Pancreatic Cancer Chemoresistance to Gemcitabine.
Amrutkar M, Gladhaug IP. · 2017
Read Pancreatic Cancer Chemoresistance to Gemcitabine. by Amrutkar M, Gladhaug IP. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5704175.txt.
Description
Amrutkar and co-authors review resistance to gemcitabine in pancreatic cancer. Their review appeared in Cancers. Pancreatic cancer is often found late. It spreads early and responds poorly to drugs. Gemcitabine remains a core treatment at all stages. Resistance often develops within weeks.
The review explains how the drug works. Uptake and activation steps can fail. Tumour stroma also blocks its effects. New strategies aim to bypass resistance. Chemists are building modified prodrug versions. Others trap the drug in nanoparticles or liposomes. Many beat plain gemcitabine in cells and mice. Clinical use is still at an early stage. The authors map the full resistance pathway.
Catalog record
| CREATOR | Amrutkar M, Gladhaug IP. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 90 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |